Showing posts with label nhs. Show all posts
Showing posts with label nhs. Show all posts

Thursday, 1 December 2016

The Role of Crystallins in Maintaining Lens Transparency

Crystallins are adapted not to crystallise; the eye lens needs to be a highly concentrated solution, but it needs to avoid small crystals or aggregates, since they would scatter light and make the lens opaque. Our lenses achieve this by mixing together several different crystallins, which together form a uniform, glassy solution. The protein molecules are arranged in a way which means that their refractive index is nearly the same as glass- which makes the lens transparent. This is due to the small size of the protein molecules, less than 10 nm in diameter, and their close packing at high concentration
The lens contains three major types of crystallins, making up about 90% of the protein. Alpha crystallins are the most common. They are composed of two similar types of protein chain, which associate to form large spherical complexes containing about 40 chains. These large spheres repel one another and distribute themselves throughout the lens cells. Beta crystallins, shown here from, also form oligomeric complexes (contains a limited number of monomers), typically formed of two or six copies of the chain. There are several similar beta crystallins, which can mix and match to form a bunch of different types of oligomers. Finally, gamma crystallins are monomeric, and serve as a weak glue to gently bind the alpha crystallins together.

Our crystallin proteins need to last our entire life, so the lens contains a powerful method to protect them. Alpha crystallin acts as chaperone, finding damaged proteins and binding to them before they can form translucent or opaque complexes. Unfortunately, in spite of this protection, the damage builds up as we age, as crystallins are broken or unfolded or oxidized. Slowly, the damage leads to progressive build-up of opaque aggregates, leading to cataracts. 

Sunday, 27 November 2016

The NHS

The NHS was launched in 1948. It was born out of a long-held concept that healthcare should be available to all, regardless of wealth – one of the NHS's core principles. With the exception of some charges, such as prescriptions, optical services and dental services, the NHS in England remains free at the point of use for all UK residents. This currently stands at more than 64.6 million people in the UK.

The NHS in England deals with over 1 million patients every 36 hours. It employs more than 1.5 million people, putting it in the top five of the world’s largest workforces, alongside the US Department of Defence, McDonalds, Walmart and the Chinese People’s Liberation Army.

The NHS in England is the biggest part of the system by far, catering to a population of 54.3 million and employing around 1.2 million people. Of those, the clinically qualified staff include 150,273 doctors, 40,584 GPs, 314,966 nurses and health visitors, 18,862 ambulance staff, and 111,127 hospital and community health service (HCHS) medical and dental staff. The NHS in Scotland, Wales and Northern Ireland employs 161,415; 84,000 and 66,000 people respectively.

Funding for the NHS comes directly from taxation. Since the NHS transformation in 2013, the NHS payment system has become underpinned by legislation. The Health & Social Care Act 2012 moves responsibility for pricing from the Department of Health, to a shared responsibility for NHS England and NHS Improvement. The purpose of the 2012 act was to devolve decision-making from a centralised NHS to local communities, with the intent of making it more tailored to specific needs. The act aimed to put patients at the centre of the NHS, change the emphasis of measurement to clinical outcomes, and empower healthcare professionals, in particular GPs.


When the NHS was launched in 1948, it had a budget of £437 million (roughly £15 billion today).For 2015/16, the overall NHS budget was around £116.4 billion, with NHS England  managing £101.3 billion of this.

Thursday, 19 May 2016

Trichromatic vision in Humans

The human eye is the visual pathway to the world around us, and enables most of us to see thousands upon thousands of different colours. As shown in figure 1, the human eye is a very complex organ, with many different structures help us get the best vision in different situations- dim or bright etc. - and when all of these parts perform in harmony, we are able to see clearly.

In order to understand how we see different colours, it is first imperative to understand how the eye works as a unit: the starting point of vision is when light rays reflect off an object and enter the eyes through the cornea-the outermost, transparent layer of the eye. The rays are then refracted by the cornea and pass through the pupil- a whole created by the iris to control the amount of light passing through it. After that the rays pass through the lens- which can bulge or shrink to further refract the rays in order to focus them on the retina at the back of the eye.

The retina is an extremely thin layer of cells at the back of the eye which contains millions of light-sensitive cells called rods and cones- and are also known as photoreceptors. Cones are concentrated in the center of the retina (the macula) and in bright light conditions, they provide precise vision and detect colours. Rods however, are located outside the macula and extend all the way to the outer edge of the retina. They provide peripheral vision and allow the eyes to detect motion and help us see in dim light and at night. These photoreceptors then convert the light into electrical impulses which are sent to the brain via the optic nerve at the back of the eye, and create an image in our head.

As previously mentioned, we are able to see colours due to cone photoreceptors, of which there are 6-7 million of in the retina of each eye. Most of them are located in a 0.3mm spot on the retina called the fovea centralis, and over the last few centuries experiments have given evidence that amoung these cones there are three different types of colour reception: red (64%), blue (2%) and green (34%). This was proved by two different groups of scientists: Wald and Brown at Harvard, and Marks, Dobelle and MacNichol at Hopkins in 1959. However, the first original theory of there being three different light sensitive ‘particles’ was put forward by Thomas Young in 1802, 136 years after Sir Isaac Newton’s famous discovery that white light contained thousands of different colours (due to their different wavelengths on the electromagnetic spectrum), and so enabled us to understand where colour ‘comes from’.

"Colour is the visual effect that is caused by the spectral composition of the light emitted, transmitted, or reflected by objects” and when a light ray of a certain wavelength hits the fovea centralis, it activates the three different types of cone to varying degrees, and with an infinite amount of varying combinations, we are able to see thousands of different colours. This is shown in a simplified diagram in figure 3, but in reality this diagram would be a lot more complex because of the ranging number of shades which belong to each colour. To prove that any colour visible to humans can be created from this trichromatic system, we can use the example of TV sets; if you look at a normal television up close when it is switched on, the tiny pixels contain just 3 colours: red, blue and green (as shown in figure 4).

The human eye can perceive many more variations in warmer colours than cooler ones due to the fact that almost 2/3 of the cones process longer light wavelengths and so we are able to see more yellows, oranges and reds. Additionally, the reason we can’t see colours in the dark is because the rods ‘take over’ to control the amount of light that we see, and so the cones aren’t in control anymore. Furthermore, about 8% of men and 1% of women have some type of colour impairment; the most common of which is red and green dichromatism, which causes the colours red and green to appear indistinguishable.


In conclusion the reason why humans can see thousands upon thousands of different colours is that, despite only having 3 types of cone photoreceptor, the cones send-off varying amounts of blue, red and green to the optic nerve to be carried to the brain, and by changing these amounts of light, all of the colours in the visible spectrum can be produced.

Sunday, 24 April 2016

Analgesics and Anaesthetics

An analgesic is a drug acting to relieve pain, and this group of drugs include aspirin, paracetamol and ibuprofen[1]. These three drugs all fall under the most common type of analgesic- non-opioid analgesics. This group of simple painkillers work by blocking the COX-2 enzyme which is responsible for pain and inflammation[2]. The stronger groups of painkillers are compound and opioid analgesics, and these are widely used in hospitals for severe pain.

Aspirin is one of the most common analgesics used today[3]- the very first use of this drug dates back to ancient Asian records 2400 years ago, as a related compound from willow bark had been used to relieve pain and treat fevers[4]. The use of this compound then grew in the 18th Century, with Edward Stone reading a paper to the Royal Society of London on the effect of willow bark on Malaria. In the 1840s, nearly 100 years later, organic chemists identified this active ingredient as salicin- which was found to be converted into salicylic acid in the body by Pr. Von Nencki in 1870. This was then given to patients to help with fevers, however a common and unpleasant side effect was soon discovered; severe irritation of the lining of the mouth, gullet and stomach.

To combat this chemists made sodium salicylate to cause less painful side effects, but it tasted awful and so patients were not keen on taking it. This also caused patients to vomit and so was not an ideal painkiller. In the 1890s Felix Hofmann of the Bayer (a German pharmaceutical company) synthesized a similar drug which was found to have good medicinal properties and be less irritable towards membranes in the body; aspirin had now been made.

Aspirin, or 2-Ethanoyloxybenenecarboxylic acid, was sent off for clinical trials and was finally patented by Bayer in 1898[5]. John Vare won the Nobel Prize for medicine in 1982 for discovering that aspirin inhibits the COX-2 enzyme in the prostaglandin pathway, and this drug is now one of the most manufactured in the world, with 10 million kilograms being made in the US each year.
An anaesthetic is a drug that causes anaesthesia, which is a reversible loss of sensation[6]. These contrast with analgesics, which relieve pain without eliminating sensation. These drugs are generally given to perform surgery or an invasive surgery, which would be very painful if the area could be felt by the patient. The main two types of anaesthetic are local and general anaesthetics.

Local anaesthetic is a form of medication that causes reversible absence of pain sensation in a localised area, although other senses can also be affected. Paralysis can also be achieved by this type of anaesthetic when used on specific nervous pathways[7] (this is known as an epidural, and is commonly used during a caesarean section during childbirth). The other two main types of local anaesthetic are topical and subcutaneous anaesthesia. Topical anesthesia is a local anesthetic which is applied directly to the skin- mostly in the form of a gel or a cream. Subcutaneous anesthesia as local anesthetic applied directly under the skin, mostly in the form of an injection, targeted at the nerves which stimulate pain in that specific area.

A common local anaesthetic is lidocaine[8], and we can use this example to see how many other local anaesthetics work. The main action of this drug is to inhibit the movement of sodium into nerve cells, but why does this effectively stop the feeling of pain? Figure 5 shows a representation of an electrical signal inside a nerve cell (axon), and how sodium ions move through sodium channels to stimulate the feeling of pain[9]. It then shows how lidocaine- represented as a red circle- blocks these channels and so does not allow the sodium to pass through the channel, and does not allow the electrical signal travel to the brain.

Figure 6 is a magnified version of figure 5 and shows the cellular membrane interactions with the lidocaine molecules. The 'sodium channel' spans the phospholipid bilayer on the membrane of the cell and is extremely narrow.  The anaesthetic binds much more tightly to the channel when charged due to electrostatic interactions, and so helps block the sodium channels and make the area temporarily numb[10].
For more serious circumstances, when a patient has to be completely unaware, doctors use general anaesthesia. This renders patients unconscious with no perception or memory of the surgery while it is happening. It also limits the physiological responses to invasive procedures and surgical cuts, keeping blood pressure, stress hormone release and heart rate constant during the operation.
General anaesthesia is still quite a mystery to the scientific world[11], as the biochemical mechanism which controls it is still speculated about. To induce unconsciousness, anaesthetics have different sites of action and affect the central nervous system at varying levels of severity. Common areas of the CNS whose functions are often interrupted or changed during general anaesthesia include the cerebral cortex, thalamus, and spinal cord.

Paul Ehrlich stated that drugs act only when they are bound to their receptors; however, this concept does not seem to apply in the case of general anaesthetics. There are two main reasons to support this concept:
·      
            The molecular structures of these anaesthetics are very simple and different to one another


, and so there is no obvious structure-activity relationship
      Most general anaesthetics have very weak affinities for their targets acting at much higher concentrations than most other drugs
In 2015, roughly 15 million operations and minor procedures were carried out in the UK alone, and this would never have been able to happen without anaesthetics.



[1] http://www.nhs.uk/ipgmedia/national/Arthritis%20Research%20UK/Assets/Painkillers-analgesics.pdf
[2] http://www.arthritisresearchuk.org/arthritis-information/drugs/painkillers.aspx
[3] http://www.drugs.com/aspirin.html
[4] https://en.wikipedia.org/wiki/Aspirin
[5] https://en.wikipedia.org/wiki/History_of_aspirin#World_War_I_and_Bayer
[6] http://www.nhs.uk/Conditions/Anaesthesia/Pages/Introduction.aspx
[7] http://patient.info/doctor/practical-local-anaesthesia
[9] https://www.evidence.nhs.uk/formulary/bnf/current/15-anaesthesia/152-local-anaesthesia
[10] http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075196/
[11] https://www.newscientist.com/article/mg21228402-300-banishing-consciousness-the-mystery-of-anaesthesia/

Friday, 4 March 2016

The wonders of ECMO


The extra-corporal membrane oxygenation machine is one of the wonders of 20th and 21st century medicine, as it acts as an artificial lung outside of the body, oxygenating the blood and pumping it round.

ECMO was first used successfully in the USA in 1976 and was introduced in the UK in 1989. It was first set up in a paediatric setting at Great Ormond Street Hospital in 1992 and to date they have supported over 850 babies and children. This is of vital significance as ECMO machines are mostly used on children and babies, but are sometimes used in adults with cardiac and respiratory failure.

There are two main types of ECMO: veno-arterial and veno-venous. In both types, blood drained from the venous system is oxygenated outside of the body. In VA ECMO, this blood is returned to the arterial system and in VV ECMO the blood is returned to the venous system- in this typr of ECMO there is no cardiac support.

In veno-arterial ECMO, a venous cannula is placed in the right common femoral vein for extraction and an arterial cannula is placed into the right femoral artery for infusion. The tip of the femoral venous cannula should be kept near the junction of the inferior vena cava and right atrium, while the tip of the femoral arterial cannula should be kept in the iliac artery. Central VA ECMO may be used if cardiopulmonary bypass has already been established (with cannulae in the right atrium and ascending aorta).

In veno-venous ECMO cannulae are usually placed in the right common femoral vein for drainage and right internal jugular vein for infusion. Alternatively, a dual-lumen catheter is inserted into the right internal jugular vein, draining blood from the superior and inferior vena cava and returning it to the right atrium

ECMO can be used in the operating theatre straight after surgery or on one of the intensive care units. If a patient is going through ECMO after cardiac surgery, the surgeon will usually insert the cannulae (tubes) during the operation, directly into the heart through the chest. Whereas, if ECMO is started in the intensive care unit, the cannulae connecting the patient to the ECMO circuit are placed directly into the blood vessels on the side of the neck.

Once in place, the cannulae are then connected to the ECMO circuit. Dark deoxygenated blood drains from the patient through the tube in the vein and is pumped through the membrane oxygenator where carbon dioxide is removed and oxygen added. The blood is then re-warmed and returned to the body. This process goes on continuously while the patient is on ECMO. Additionally, they will also stay on a ventilator but on very gentle settings which allow the lungs to rest.